# SWOG NCORP Research Base Clinical Trials Workshop

Thursday, October 8, 2026, 8:00 am to 11:00 am CT
Hyatt Regency Chicago

## Agenda

### General Session (Regency D, Ballroom Level) **(Hybrid)**

**Welcome and SWOG NCORP Research Base Overview**

Sam Dzingle, Clinical Research Data Coordinator, SWOG Statistics and Data Management Center

**Recruitment and Retention Committee Membership Announcement**

Kamara Mertz-Rivera, MA, CCRC
Director of Clinical Research and Administrator, Upstate Carolina NCORP

### Cancer Care Delivery Research

**NCI Cancer Care Delivery Research (CCDR) Update**

Ashley Buscetta, MSN, FNP-BC, CWOCN
CCDR Operations Lead, Program Official, Healthcare Delivery Research Program
NCI Division of Cancer Control and Population Sciences

### Clinical Trials

**Drug Costs in Federally Sponsored Cancer Clinical Trials**

Joseph Unger, PhD, MS
Chair of the SWOG NCORP Research Base, SWOG Statistics and Data Management Center

**Bringing the Patient Voice into SWOG Clinical Trials: Best Practices for Patient-Reported Outcomes**

Katie Arnold, MS
Statistical Associate, SWOG Statistics and Data Management Center

### Clinical Trial Perspectives: Participant Trust and Clinical Trials

**The Patient's Perspective**

Marielle McLeod, MHA
SWOG Patient Advocate: Gastrointestinal Committee

**What Are We Asking Patients to Trust? Lessons from the Institutional Medical Mistrust Scale**

Marilyn Baffoe-Bonnie, PhD, MBE
Assistant Professor, Center for Health Justice and Bioethics, Lewis Katz School of Medicine, Temple University

**Words Matter: How Plain Language Can Help You Build Trust with Patients and Successfully Communicate Your Message**

Andrea Mongler, MPH
Plain Language Communications Expert, SWOG Network Operations Office

### General Session Close *(In-Person: Transition to Breakout Sessions)*

SWOG CANCER RESEARCH NETWORK | NCI Community Oncology Research Program
A program of the National Cancer Institute of the National Institutes of Health

*A HOPE FOUNDATION sponsored Clinical Trials Training Course for Studies in*
*Cancer Care Delivery, Palliative Care, Prevention, Screening and Surveillance, and Symptom Management and Survivorship*

## **Breakout Q & A Discussion Sessions** (Concourse and Ballroom Levels) **(In-person Only)**

**You're invited to attend three discussion sessions. Please select one topic for each session time:**

| | **Breakout Room 1**<br>**Comiskey**<br>**(Concourse Level)** | **Breakout Room 2**<br>**Hong Kong**<br>**(Ballroom Level)** | **Breakout Room 3**<br>**Toronto**<br>**(Ballroom Level)** |
|---|---|---|---|
| **Session 1**<br>**9:35 – 10:00 am** | Continuing the Conversation: Building Trust with Patients | Let's Talk PROs: The Patient Voice in SWOG Clinical Trials | S2417CD: Promote Guideline Concordant CRC Surveillance |
| **Session 2**<br>**10:05 -10:30 am** | Continuing the Conversation: Building Trust with Patients | Let's Talk PROs: The Patient Voice in SWOG Clinical Trials | S2417CD: Promote Guideline Concordant CRC Surveillance |
| **Session 3**<br>**10:35 – 11:00 am** | Continuing the Conversation: Building Trust with Patients | Let's Talk PROs: The Patient Voice in SWOG Clinical Trials | Newly Activated S2424CD: A-PACT Intervention |

## Discussion Session Descriptions

### Session 1 (9:35 am), 2 (10:05 am) and 3 (10:35 am) - Choose 1 topic per session time.

- ☐ **Continuing the Conversation: Building Trust with Patients** ***(Comiskey / Concourse Level / Sessions 1, 2 & 3)***
  Have questions or want to dig deeper into the ideas about building trust shared during the General Session? Join presenters Dr. Baffoe-Bonnie and Andrea Mongler, and site representative Samantha Wright, CCRP (Carle Cancer Center NCORP) for an interactive Q&A and discussion about medical mistrust and the power of plain language. Bring your questions, experiences, and challenges as we explore practical ways to better understand perspectives and communicate in ways that foster trust.

- ☐ **Let's Talk PROs: The Patient Voice in SWOG Clinical Trials** ***(Hong Kong / Ballroom Level / Sessions 1, 2 & 3)***
  Please join in a discussion about patient-reported outcome (PRO) best practices. This interactive session offers an opportunity to ask questions, share experiences, and discuss challenges that arise when collecting PRO data in SWOG clinical trials. Join Katie Arnold, biostatistician and SWOG PRO Core Team member (Statistics and Data Management Center), and Erin Fukaya, Clinical Operations Manager (The Hawaii NCORP), who will share perspectives from both the study and site level as we consider strategies for supporting high-quality PRO data collection while keeping the participant experience in mind.

- ☐ **S2417CD: Helping to Promote Guideline Concordant Colorectal Cancer Surveillance – Q&A for NCORP Sites** ***(Toronto / Ballroom Level / Sessions 1 & 2)***
  The transition from curative-intent treatment to survivorship can be overwhelming for patients with colorectal cancer (CRC), particularly when navigating recommended surveillance. S2417CD, *A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance* is designed to improve follow-up care for CRC survivors. This study is currently open to accrual through NCORP sites. Study Chair, Dr. Christine Veenstra, and S2417CD Project Coordinator (University of Michigan), Anupriya Sharma, will provide an overview of the study, discuss study participation and implementation, and answer questions about this important trial.

- ☐ **Newly Activated S2424CD A-PACT Intervention: A New SWOG Cancer Care Delivery Trial** ***(Toronto / Ballroom Level / Session 3)***
  Join S2424CD Study Chair, Dr. Ravi Parikh and Project Manager (Emory University), Ajla Pleho, for an information session on the newly activated, *A Randomized Controlled Trial of an Intervention Called "Algorithm-Enabled Patients Activated in Cancer Care Through Teams (A-PACT) to Improve Goals of Care Communication for People with Cancer*. Designed to enhance goals-of-care communication between people with cancer and their care teams, this study features an automated screening tool/algorithm to streamline enrollment and reduce site workload. The trial requires early collaboration between site IT teams and Dr. Parikh's group at Emory University. Dr. Bernard Tawfik (New Mexico NCORP) will share their experience on implementing the algorithm at their site. Attend this session to hear more about this newly activated study and how your NCORP site can participate in this trial.

***In-Person Attendees: Please turn in your completed Feedback Form at the last Breakout Session you attend.***
***We also encourage you to submit topics for future SWOG NCORP Clinical Trials Workshops.***

SWOG CANCER RESEARCH NETWORK | NCI Community Oncology Research Program
A program of the National Cancer Institute of the National Institutes of Health

*A HOPE FOUNDATION sponsored Clinical Trials Training Course for Studies in*
*Cancer Prevention, Screening, Supportive Care and Symptom Management, Surveillance, HR-QOL and Cancer Care Delivery*

# SWOG NCORP Research Base Clinical Trials Workshop

Thursday, October 8, 2026
Chicago, Illinois

General Session: 8:00 am – 9:30 am CT
Breakout Sessions: 9:30 am – 11:00 am CT

**Certification of Attendance:**

I certify that I attended _____ hours of this meeting. The topics of the meeting contribute to education and professional advancement in clinical research.

Attendee Name _____

Attendee Signature _____

Date _____

**Program Director, SWOG NCORP Data Management:**
Monica Yee, CCRP — monicay@crab.org

*A HOPE FOUNDATION sponsored Clinical Trials Training Course for Studies in*
*Cancer Prevention, Screening, Supportive Care and Symptom Management, Surveillance, HR-QOL and Cancer Care Delivery*

# SWOG NCORP Research Base Clinical Trials
# Accruing Studies

| Study # | Study Title | Activation / Status | Accrual | Follow-up (from Reg Date) | Participating Sites |
|---|---|---|---|---|---|
| **Cancer Care Delivery Research Committee** | | | | | |
| S1703 | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer | July 2018<br>**Step 1 Closed August 2026**<br>**Step 2 is Open** | Step 1: 701 of 739<br><br>Step 2: 477 of 498 (**95%)** | 6 years from Step 2 randomization date | NCTN and NCORP |
| S2417CD | A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance | August 2025 | Patient: 132 of 654 (**20%**)<br>Non-patient: 75 of 393 (**19%**) | 1.5 years | NCORP Only |
| S2424CD | A Randomized Controlled Trial of an Intervention Called" Algorithm-Enabled Patients Activated in Cancer Care Through Teams" (A-PACT) to Improve Goals of Care Communication for People with Cancer | June 2026<br>**Newly Activated** | 5 of 1000 | 1 year | NCORP Only |
| **Palliative Care Committee** | | | | | |
| S1501 | Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity, Phase III | September 2017 | 399 of 491<br>**81%** | 2 years from Step 2 randomization date | NCTN and NCORP |
| S2408 | A Randomized Phase III Blinded Trial of Lanreotide for The Prevention of Postoperative Pancreatic Fistula | February 2025<br>**Temp Closure** | 63 of 274<br>**23%** | 1 year from surgery date | NCTN and NCORP |
| **Prevention, Screening, and Surveillance Committee** | | | | | |
| | New protocol under development; activating 2027. | | | | |
| **Symptom Management and Survivorship Committee** | | | | | |
| S2013 | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | August 2021 | 2656 of 3609<br>**74%** | 1 year | NCORP Only |
| S2205 | Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy | March 2023 | 683 of 777<br>**88%** | 1 year | NCTN and NCORP Limited institution |

# SWOG NCORP Research Base Clinical Trials
# Completed Accrual with Participants in Active Follow-up

| Study # | Study Title | Activation/ Accrual Closure | Accrual | Follow-up Length from Reg Date | Participating Sites |
|---|---|---|---|---|---|
| **Cancer Care Delivery Research Committee** | | | | | |
| S2108CD | A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy | August 2022 **Accrual Complete November 2024** | 1284 of 1282 | 2 years | NCORP Only Limited Institution |
| **Prevention, Screening and Surveillance Committee** | | | | | |
| S0820 | A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | March 2013 **Accrual Complete June 2023** | 354 of 389 | 8 years | NCTN and NCORP |
| S1823 | A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early-Stage Germ Cell Tumors | June 2020 **Accrual Complete May 2024** | 964 of 956 | 3 years | NCTN and NCORP |
| S1904 | Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE) | September 2020 **Accrual Complete June 2024** | 412 of 415 | 5 years | Limited institution |
| **Symptom Management and Survivorship Committee** | | | | | |
| S1600 | A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes | February 2019 **Accrual Complete October 2023** | 203 of 200 | 3 years (post-cystectomy date) | NCTN and NCORP |
| S1714 | A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients **See Revision #8 and Note to File for requirements for a Consent Addendum (for imaging)** | March 2019 **Closed Nov 2021** | 1336 of 1336 | 3 years (post-cystectomy date) | NCTN and NCORP |
| S2010 | A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN) | January 2023 **Accrual Complete January 2025** | 565 of 540 | 1.5 years | NCTN and NCORP |

Questions? Contact cancercontrolquestion@crab.org